The global Hepatitis Testing Market worth $3.6 billion by 2026, growing at a CAGR of 4.7% in the upcoming years.

The growth of the global market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis. High cost of nucleic acid tests, lack of mandates for nucleic acid tests in developing countries and unfavorable reimbursement scenarios are expected to restrain hepatitis market growth. Emerging markets, rising technological advancements in molecular diagnostics, and growth in the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players in the market. In contrast, changing regulatory landscape, operational barriers and shortage of skilled professionals may challenge market growth to a certain extent. The market is segmented based on disease type, technology, end user, and region.

Download a FREE Sample Report PDF of the Global Hepatitis Testing Market Research Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139802887utm_source=Ganeshutm_medium=P

Key Market Players:

1. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), bioMérieux SA (France), DiaSorin S.P.A. (Italy), Ortho Clinical Diagnostics (US), MedMira Inc. (Canada), Fujirebio US, Inc. (Japan), Grifols, S.A. (Spain), Orasure Technologies (US), GenMark Diagnostics Inc. (US), Vela Diagnostics (Singapore), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), geneOmbio Technologies Pvt. Ltd. (India), and Molbio Diagnostics Pvt. Ltd. (India).

Upcoming Changes in the Hepatitis Testing Market Report

• Changes in the market scope: The current report includes the historical data for the market.
• New and improved representation of financial information: The new edition of the report provides updated financial information till 2020 (depending on availability) for each listed company in a graphical representation in a single diagram (instead of multiple tables). This will allow for the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, and business segment focus in terms of the highest revenue-generating segment.
• Recent market developments: Recent developments help understand market trends and growth strategies adopted by players in the market. For instance, the number of product launches in this market has increased in the last three years (2018 to 2021).
• Latest product portfolio: The new edition of the report provides an updated product portfolio of the companies profiled in the report.
• Company profiles: Nine additional company profiles have been added (a total of 20 companies are profiled).
• Competitive leadership mapping: This edition of the report includes a comprehensive study of companies’ rankings and capabilities. The top vendors in the market have been evaluated in this section. A similar analysis has been conducted for start-ups/SMEs.
• COVID-19 impact: The current edition of the report covers the COVID-19 impact on the market. Additional points in the market overview section have been added, keeping in mind the impact of COVID-19 on the market.

This report categorizes the hepatitis testing market into the following segments and sub-segments:

By Disease Type

• Hepatitis B (HBV)
• Hepatitis C (HCV)
• Other Hepatitis Diseases

By Technology

• Enzyme-linked Immunosorbent Assay (ELISA)
• Rapid Diagnostic Tests (RDT)
• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Other Technologies

By End User

• Hospital Diagnostic Laboratries
• Blood Banks
• Other End Users

By Region

• North America
• US
• Canada
• Europe
• Germany
• UK
• Rest of Europe
• Asia Pacific
• Rest of the World

Hepatitis B segment dominated the Hepatitis testing market in 2020.

Based on disease type, the market is segmented into hepatitis B, hepatitis C, and other hepatitis diseases (hepatitis A, D, and E). The hepatitis B segment accounted for the largest share of the market in 2020. Factors such as the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of nucleic acid tests for HBV diagnosis are driving the growth of this market segment.

Direct Purchase of the Global Hepatitis Testing Market Research Report at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=139802887utm_source=Ganeshutm_medium=P

The ELISA segment of hepatitis testing market, to witness the highest market share during the forecast period.

Based on technology, the market is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), and other technologies (such as sequencing, mass spectrometry, and western blotting). The ELISA segment accounted for the largest share of the market in 2020. The large share of this segment can primarily be attributed to the wide acceptance of this test in clinical practices to diagnose hepatitis.

North America was the largest regional market for hepatitis testing market in 2020.

The global market is segmented into North America (the US and Canada), Europe (Germany, the UK, and the Rest of Europe), Asia Pacific, and Rest of the World. In 2020, North America dominates the global market, and this trend is expected to continue during the forecast period. The large share and high growth of this region can be attributed to the rising prevalence of hepatitis and increased research and clinical trials for hepatitis testing in the US.